Abstract | PURPOSE: PATIENTS AND METHODS: RESULTS: All patients responded to rasburicase, as defined by normalization of UA levels maintained during chemotherapy. The control of UA was obtained within 4 hours after the first injection of the drug. Creatinine levels and other metabolites were also controlled with the administration of rasburicase. No patient exhibited increased creatinine levels or required dialysis during chemotherapy. CONCLUSION:
|
Authors | Bertrand Coiffier, Nicolas Mounier, Serge Bologna, Christophe Fermé, Hervé Tilly, Anne Sonet, Bernard Christian, Olivier Casasnovas, Eric Jourdan, Karim Belhadj, Raoul Herbrecht, Groupe d'Etude des Lymphomes de l'Adulte Trial on Rasburicase Activity in Adult Lymphoma |
Journal | Journal of clinical oncology : official journal of the American Society of Clinical Oncology
(J Clin Oncol)
Vol. 21
Issue 23
Pg. 4402-6
(Dec 01 2003)
ISSN: 0732-183X [Print] United States |
PMID | 14581437
(Publication Type: Clinical Trial, Clinical Trial, Phase II, Journal Article)
|
Chemical References |
- Antineoplastic Agents
- Recombinant Proteins
- rasburicase
- Uric Acid
- Creatinine
- Urate Oxidase
|
Topics |
- Adult
- Aged
- Aged, 80 and over
- Antineoplastic Agents
(therapeutic use)
- Creatinine
(blood)
- Female
- Humans
- Hyperuricemia
(drug therapy, etiology, prevention & control)
- Injections, Intravenous
- Lymphoma, Non-Hodgkin
(drug therapy)
- Male
- Middle Aged
- Recombinant Proteins
(therapeutic use)
- Remission Induction
- Safety
- Treatment Outcome
- Tumor Lysis Syndrome
(drug therapy, etiology)
- Urate Oxidase
(therapeutic use)
- Uric Acid
(blood)
|